Back Hepatitis C

Hepatitis C

HIVandHepatitis.com 2017 Conference Coverage

Article listings by topic for HIVandHepatitis.com conference coverage in 2017, including the Conference on Retroviruses and Opportunistic Infections, EASL International Liver Congress, IAS Conference on HIV Science, and AASLD Liver Meeting.

alt

AASLD 2017: Nivolumab Improves Outcomes in Liver Cancer Study

Nivolumab (Opdivo), a PD-1 checkpoint inhibitor that helps the immune system fight cancer, was associated with a decrease in tumor size or disease stabilization in patients with hepatocellular carcinoma (HCC) in the CheckMate 040 study, according to a report at the 2017 AASLD Liver Meeting last month in Washington, DC.

alt

Coverage of the 2017 AASLD Liver Meeting

HIVandHepatitis.com coverage of the 2017 Liver Meeting, the annual conference of the American Association for the Study of Liver Diseases, AASLD), October 20-24, 2017, in Washington, DC.

alt

AASLD 2017: More Work and Lower Drug Prices Needed to Eliminate Hepatitis C Worldwide

Eliminating hepatitis C virus (HCV) as a global public health concern is feasible, but to do so more people need to be tested and treated, and prices of direct-acting antivirals need to come down, according to presentations at the AASLD Liver Meeting last month in Washington, DC.

alt

AASLD 2017: Model Shows Hepatitis C Treatment is Cost-Effective in Japan

Treatment of chronic hepatitis C with direct-acting antivirals can lead to substantial savings by preventing the development of liver failure and liver cancer, according to a mathematical modeling study presented at the AASLD Liver Meeting in October in Washington, DC.

alt

AASLD 2017: Sofosbuvir/Ledipasvir for 8 Weeks Cures Acute HCV in People with HIV

An 8-week course of sofosbuvir/ledipasvir (Harvoni) led to sustained response in all HIV-positive with genotype 1 or 4 acute hepatitis C virus (HCV) infection in the SWIFT-C study, according to a reportat the AASLD Liver Meeting last month in Washington, DC.

alt

AASLD 2017: Hepatitis C Testing Linked to Reduced Opioid Use

Getting tested for hepatitis C virus (HCV) was associated with reduced drug use, especially among those who tested positive, but evenpeople who tested negative saw some reduction, according to study results presented at the AASLD Liver Meeting in October in Washington, DC.

alt

AASLD 2017: Sofosbuvir/Ledipasvir for 8 Weeks Cures Acute HCV in People with HIV

An 8-week course of sofosbuvir/ledipasvir (Harvoni) led to sustained response in all HIV-positive with genotype 1 or 4 acute hepatitis C virus (HCV) infection in the SWIFT-C study, according to a reportat the AASLD Liver Meeting last month in Washington, DC.

alt

AASLD 2017: Curing Hepatitis C Leads to Improved Quality of Life

People who were cured of hepatitis C with direct-acting antivirals had sustained improvements in their health-related quality of life, including both physical and mental health measures, according to study results presented at the AASLD Liver Meeting last week in Washington, DC.

alt